SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced the submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ...

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today reported first quarter results and business highlights for the quarter ended March 31, ...

The curing sickle cell through gene therapy story is a long way from being written. But it’s for sure that it has not gone ...

In this photo illustration, a Bluebird bio logo is seen on a smartphone. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images) Last month, I wrote about the company bluebird ...

Once a rising star in the biotech industry, Bluebird Bio (NASDAQ: BLUE) has had a difficult past few years. The company's shares are down by 94% since late 2018, a horrible performance by any metric.

For investors in gene therapy biotech bluebird bio, a wait-and-see approach toward a proposed acquisition has paid off. In a revised merger agreement, Carlyle and SK Capital Partners are now offering ...

Benjamin Graham and Warren Buffett may urge investors to buy when there's blood on the streets, but even the best advice has its limitations. In the case of Bluebird Bio (NASDAQ: BLUE) stock, there's ...

Add Yahoo as a preferred source to see more of our stories on Google. Former Bluebird Bio CEO Nick Leschly, speaking at the opening of a Houston cell and gene therapy facility in 2018Daniel ...

CAMBRIDGE, MA: Senior research associate Lauryn Christiansen works on lentiviral gene delivery into stem cells. The work is for the treatment of ALD, Thalassemia and Sickle Cell Anemia. Bluebird bio, ...

Genetix CEO David Meek says the company is profitable after acquiring bluebird bio's gene therapy assets and shows that the ...

Bluebird Bio, Inc. (NASDAQ:BLUE) shares are trading higher Friday after Morgan Stanley upgraded Bluebird Bio from Underweight to Equal-Weight and raised the price target to $7. Morgan Stanley analyst ...

Earlier this month, Bluebird Bio's shareholders probably felt like winners as the stock had rallied from $3 in mid-November to nearly $5 for a hot minute. Then came a regulatory clearance for Bluebird ...